When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantification and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy

Amyloid-targeting therapies (ATTs) substantially reduce amyloid PET signal and slow clinical decline in early symptomatic Alzheimer disease. As ATTs enter clinical practice, PET may assess target engagement and guide treatment management, but there is no consensus on how to measure treatment-related amyloid clearance (TRAC). We compared Centiloid quantification across pipelines and visual reads for interpreting pre- and post-ATT amyloid PET. Methods: We analyzed 18F-florbetapir or 18F-florbetaben PET from 101 patients treated with lecanemab or donanemab: 88 pre-ATT and 54 post-ATT scans, inclu

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.